CSL invests $355 million in kidney and liver drug Hover Preview
Margin Watch

CSL invests $355 million in kidney and liver drug

By Crystal Fisher 156 Views October 5, 2026
Read Article

Recent News

View All →

Margin Watch

Shelf Reports

Vendor Ledger

All Post

Margin Watch

CSL invests $355 million in kidney and liver drug

CSL pledges $355 million to co-develop lixudebart with Alentis Therapeutics, a kidney liver drug for rare disorders entering phase II RENAL F02 trial.

Crystal Fisher 217 Views October 5, 2026
License Notes

ASX small caps have mixed week

ASX small caps had a mixed week, with S&P/ASX 200 down 0.50% and S&P/ASX Small Ordinaries down 0.56%.

Heather Simmons 203 Views October 2, 2026
Margin Watch

Australian firms set to hand out $40bn dividends

Australian dividends near $40 billion as Commonwealth Bank, Fortescue, BHP and Telstra issue payouts after the government's wealth-tax overhaul.

Crystal Fisher 249 Views October 1, 2026
Margin Watch

ASX drops on oil, bonds, and tech weakness

The ASX fell roughly 0.5% as high oil prices and climbing bond yields dampened market drive, with tech and consumer discretionary sectors leading the downturn.

Crystal Fisher 148 Views September 25, 2026